Cargando…
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684505/ https://www.ncbi.nlm.nih.gov/pubmed/38017205 http://dx.doi.org/10.1038/s41598-023-48267-2 |
_version_ | 1785151414777937920 |
---|---|
author | Quddos, Fatima Hubshman, Zachary Tegge, Allison Sane, Daniel Marti, Erin Kablinger, Anita S. Gatchalian, Kirstin M. Kelly, Amber L. DiFeliceantonio, Alexandra G. Bickel, Warren K. |
author_facet | Quddos, Fatima Hubshman, Zachary Tegge, Allison Sane, Daniel Marti, Erin Kablinger, Anita S. Gatchalian, Kirstin M. Kelly, Amber L. DiFeliceantonio, Alexandra G. Bickel, Warren K. |
author_sort | Quddos, Fatima |
collection | PubMed |
description | Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter. In this report, we conducted two studies. In the first study, we conducted an analysis of abundant social media texts. Specifically, a machine-learning based attribution mapping of ~ 68,250 posts related to GLP-1 or GLP-1/GIP agonists on the Reddit platform. Secondly, we recruited participants (n = 153; current alcohol drinkers; BMI ≥ 30) who self-reported either taking Semaglutide (GLP-1 agonist), Tirzepatide (the GLP-1/GIP combination) for ≥ 30 days or, as a control group; no medication to manage diabetes or weight loss for a within and between subject remote study. In the social media study, we report 8 major themes including effects of medications (30%); diabetes (21%); and Weight loss and obesity (19%). Among the alcohol-related posts (n = 1580), 71% were identified as craving reduction, decreased desire to drink, and other negative effects. In the remote study, we observe a significantly lower self-reported intake of alcohol, drinks per drinking episode, binge drinking odds, Alcohol Use Disorders Identification Test (AUDIT) scores, and stimulating, and sedative effects in the Semaglutide or Tirzepatide group when compared to prior to starting medication timepoint (within-subjects) and the control group (between-subjects). In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity. |
format | Online Article Text |
id | pubmed-10684505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106845052023-11-30 Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity Quddos, Fatima Hubshman, Zachary Tegge, Allison Sane, Daniel Marti, Erin Kablinger, Anita S. Gatchalian, Kirstin M. Kelly, Amber L. DiFeliceantonio, Alexandra G. Bickel, Warren K. Sci Rep Article Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1 (Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) agonists, FDA-approved for managing type 2 diabetes and obesity, where the former has shown to effectively reduce the consumption of alcohol in animal models but no reports exist on the latter. In this report, we conducted two studies. In the first study, we conducted an analysis of abundant social media texts. Specifically, a machine-learning based attribution mapping of ~ 68,250 posts related to GLP-1 or GLP-1/GIP agonists on the Reddit platform. Secondly, we recruited participants (n = 153; current alcohol drinkers; BMI ≥ 30) who self-reported either taking Semaglutide (GLP-1 agonist), Tirzepatide (the GLP-1/GIP combination) for ≥ 30 days or, as a control group; no medication to manage diabetes or weight loss for a within and between subject remote study. In the social media study, we report 8 major themes including effects of medications (30%); diabetes (21%); and Weight loss and obesity (19%). Among the alcohol-related posts (n = 1580), 71% were identified as craving reduction, decreased desire to drink, and other negative effects. In the remote study, we observe a significantly lower self-reported intake of alcohol, drinks per drinking episode, binge drinking odds, Alcohol Use Disorders Identification Test (AUDIT) scores, and stimulating, and sedative effects in the Semaglutide or Tirzepatide group when compared to prior to starting medication timepoint (within-subjects) and the control group (between-subjects). In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity. Nature Publishing Group UK 2023-11-28 /pmc/articles/PMC10684505/ /pubmed/38017205 http://dx.doi.org/10.1038/s41598-023-48267-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Quddos, Fatima Hubshman, Zachary Tegge, Allison Sane, Daniel Marti, Erin Kablinger, Anita S. Gatchalian, Kirstin M. Kelly, Amber L. DiFeliceantonio, Alexandra G. Bickel, Warren K. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity |
title | Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity |
title_full | Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity |
title_fullStr | Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity |
title_full_unstemmed | Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity |
title_short | Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity |
title_sort | semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684505/ https://www.ncbi.nlm.nih.gov/pubmed/38017205 http://dx.doi.org/10.1038/s41598-023-48267-2 |
work_keys_str_mv | AT quddosfatima semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT hubshmanzachary semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT teggeallison semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT sanedaniel semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT martierin semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT kablingeranitas semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT gatchaliankirstinm semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT kellyamberl semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT difeliceantonioalexandrag semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity AT bickelwarrenk semaglutideandtirzepatidereducealcoholconsumptioninindividualswithobesity |